I MPROVEMENT in the care of patients with cardiac disease over recent decades has been due in large measure to the development of techniques which allow quantitative evaluation of clinical problems. Thus. objective data obtained at cardiac catheterization are weighed carefully in reaching clinical decisions, and great reliance is placed on the ever increasing array of measurements forthcoming from the clinical chemistry laboratory. With growing evidence of the usefulness of measurement of circulating concentrations of cardiovascular drugs such as quinidine, procainamide, diphenylhydantoin, and lidocaine, the stage is set for exploration of the potential application of quantitation of serum or plasma cardiac glycoside levels.
The practicing cardiologist is all too well aware of the ubiquity of problems related to over-or underdigitalization. Until relatively recently, however, the digitalis glycosides have eluded reliable estimation because usual therapeutic serum concentrations are in the nanogram (10 9g) per ml range, well below the sensitivity of conventional physicochemical techniques. The availability of isotopically labeled digitalis derivatives marked the beginning of a new era in the understanding of the pharmacodynamics of cardiac glycosides. Direct measurement of radioactivity in biological fluids and tissues of selected subjects given 14C or tritium labeled glycosides yielded highly useful information concerning metabolic turnover and rates as well as routes of excretion; also the important observation was made that serum and myocardial digoxin The red cell b6Rb uptake inhibition approach takes advantage of the well-known capacity of cardiac glycosides to inhibit membrane Na-K activated adenosine triphosphatase (ATPase), an integral part of the pump mechanism which maintains high intracellular potassium and low intracellular sodium concentrations.4 Rubidium acts as a potassium analog in this system, and is used because the isotope, 86Rb, has a more convenient half-life (19 days) than available potassium isotopes. Following extraction from serum or plasma, the amount of cardiac glycoside present in a sample is estimated by comparison of its ability to inhibit active uptake of 86Rb with the inhibition produced by known amounts of digitoxin or digoxin.
Subsequent progress has been rapid, and today these two general approaches have been joined by Na-K ATPase inhibition5 and radioimmunoassay6 7 in the measurement of serum or plasma digitoxin levels. The ATPase inhibition assay of digitoxin described by Burnett Red cell 86Rb uptake inhibition3 10 and radioimmunoassayll methods are in use for determination of digoxin concentrations, and preliminary report has been made of an ATPase enzymatic isotopic displacement technique conceptually similar to radioimmunoassay.12 Greater sensitivity is required of these methods, since serum or plasma digoxin concentrations are some ten times lower than those of digitoxin. Significant discrepancies exist in reported means and ranges of serum digoxin concentrations as measured by the red cell 86Rb uptake inhibition and radioimmunoassay methods, and these remain to be resolved.
The values obtained by Marcus and coworkers13 by direct measurement of radioactivity in the blood of volunteers given maintenance doses of tritiated digoxin appear to serve as the most unequivocal source of data against which other methods may be judged. Levels in comparable subjects determined by radioimmunoassay are in close agreement with these direct measurements.", 14 The advantages and disadvantages of these various approaches have Whether methods for measurement of serum glycoside levels will be useful for diagnostic purposes in cases of questionable digitalis intoxication, however, is less easy to answer. Several studies7 10, 11, 14, 16, 2022 have demonstrated significantly higher serum or plasma digoxin or digitoxin concentrations in patients with digitalis intoxication compared with nontoxic controls. In a relatively large series of patients studied by radioimmumoassay, 90% of 131 patients without evidence of digoxin toxicity had serum levels of 2.0 ng/ml or below, while 87% of patients meeting strict criteria for digoxin intoxication had levels above 2.0 ng/ml.14 It must be noted, however, that studies published to date generally compare patients with obvious, unequivocal signs of digitalis intoxication with those in whom there are no signs or symptoms of toxicity whatever. Thus the groups compared lie at opposite ends of the clinical spectrum, where the decision to give or withold cardiac glycosides is usually straightforward. The only group of patients with equivocal electrocardiographic signs of digoxin toxicity thus far reported proved to have a mean serum digoxin concentration between those observed for obviously toxic and nontoxic patients, with substantial overlap in both directions. 14 The available evidence, then, both in the case of digoxin and of digitoxin,7 20 Pendulum swings from initial uncritical enthusiasm to disillusionment and unwarranted pessimism all too often accompany the introduction of new clinical tools. One hopes that early critical appraisal of measurement of circulating levels of cardiac glycosides will result in the establishment of an appropriate place in the diagnostic armamentarium of the clinician. Whatever that place may be, it will neither replace the need for frequent, careful observation of the patient, nor the advisability of using small increments of the more rapidly excreted forns of digitalis when problems related to dosage arise. THOMAS W. SMITH
